MBX Biosciences (MBX) Other Operating Expenses (2023 - 2026)

MBX Biosciences (MBX) reported Other Operating Expenses of $17.2 million for Q1 2026, up 185.5% sequentially from -$20.1 million in Q2 2025.

MBX Biosciences (MBX) Other Operating Expenses (2023 - 2026) Analysis & Trends

MBX Biosciences (MBX) has 4 years of Other Operating Expenses data on file, last reported at $17.2 million in Q1 2026.

For the quarter ending Q1 2026, Other Operating Expenses changed N/A year-over-year to $17.2 million; the trailing twelve-month figure through Mar 2026 stood at -$2.9 million (up 38.26% YoY), and the FY2024 full-year result was $56.1 million, up 113.1% from the prior year.
Other Operating Expenses rose to $17.2 million in Q1 2026, from -$20.1 million in the prior quarter.
In the past five years, Other Operating Expenses ranged from a high of $26.3 million in Q4 2023 to a low of -$20.1 million in Q2 2025.
A 4-year average of $949428.6 and a median of -$1.2 million in 2024 frame the typical range for Other Operating Expenses.
Across the five-year window, Other Operating Expenses slumped 44.32% in 2024 and sank 1635.81% in 2025, its largest moves.
Tracing MBX's Other Operating Expenses over 4 years: stood at $26.3 million in 2023, then tumbled by 44.32% to $14.7 million in 2024, then sank by 237.31% to -$20.1 million in 2025, then soared by 185.5% to $17.2 million in 2026.
Business Quant data shows MBX's Other Operating Expenses at $17.2 million in Q1 2026, -$20.1 million in Q2 2025, and $14.7 million in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	MBX Biosciences	2.96 Bn	2.96 Bn	-

Download Data